Search Results

Sebacia, Inc., a privately held commercial stage dermatology and aesthetics company, today provided a business update, first announcing an update to its leadership team.

Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced new positive real-world results from its two registry studies evaluating the Company’s proprietary Sebacia Microparticles in Europe and the U.S. The results were presented at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting in two oral presentations.

Sebacia, Inc. will present data showing Sebacia Microparticles could help improve dermatologic imaging by acting as a contrast enhancing agent.

Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that results from its real-world pre-conditioning study in Europe evaluating Sebacia Microparticles for treatment of facial acne has been accepted for an oral presentation

Oral presentations by Jill Waibel, MD and Merete Hædersdal, MD, PhD, DMSc

Oral presentations by Jill Waibel, MD and Ashish Bhatia, MD

Presented by leading dermatologists Jill Waibel, MD and Arielle Kauvar, MD at AAD Annual Meeting 2019

U.S. Commercial Launch of Cash-Pay Product Anticipated in Mid-2019

Oral presentation today at ASDS Annual Meeting by leading dermatologist Ashish Bhatia, MD

Oral presentations by leading dermatologists Jill Waibel, MD and Arielle Kauvar, MD